Literature DB >> 2932469

Von Willebrand's disease with spontaneous platelet aggregation induced by an abnormal plasma von Willebrand factor.

H R Grainick, S B Williams, L P McKeown, M E Rick, P Maisonneuve, C Jenneau, Y Sultan.   

Abstract

We have investigated and characterized the abnormalities in four unrelated patients with von Willebrand's disease (vWd) who have (a) enhanced ristocetin-induced platelet aggregation (RIPA) at low ristocetin concentrations, (b) absence of the largest plasma von Willebrand factor (vWf) multimers, and (c) thrombocytopenia. The platelet-rich plasma of these patients aggregates spontaneously without the addition of any agonists. When isolated normal platelets are resuspended in patient plasma spontaneous aggregation occurs; however, the patients' plasmas did not induce platelet aggregation of normal washed formalinized platelets. When the patients' platelets are suspended in normal plasma, spontaneous aggregation is not observed. The spontaneous platelet aggregation (SPA) is associated with dense granule secretion as measured by ATP release and alpha granule release as measured by beta-thromboglobulin and platelet factor 4 release. The SPA is totally inhibited by 5 mM EDTA, prostaglandin I2, and dibutryl cyclic AMP, while it is only partially inhibited by 1 mM EDTA, acetylsalicylic acid, or apyrase. A monoclonal antibody directed against glycoprotein Ib (GPIb) and/or a monoclonal antibody against the glycoprotein IIb/IIIa (GPIIb/IIIa) complex totally inhibits the SPA. The vWf was isolated from the plasma of one of these patients. The purified vWf induced platelet aggregation of normal platelets resuspended in either normal or severe vWd plasma, but the vWf did not induce platelet aggregation of normal platelets resuspended in afibrinognemic plasma. Sialic acid and galactose quantification of the patient's vWf revealed approximately a 50% reduction compared with normal vWf. These studies indicate that a form of vWd exists, which is characterized by SPA that is induced by the abnormal plasma vWf. The SPA is dependent on the presence of plasma fibrinogen, and the availability of the GPIb and the GPIIb/IIIa complex. In this variant form of vWd the abnormal vWf causes enhanced RIPA, SPA, and thrombocytopenia.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2932469      PMCID: PMC424119          DOI: 10.1172/JCI112132

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  33 in total

1.  Heterogeneity of human whole blood platelet subpopulations. II. Use of a subhuman primate model to analyze the relationship between density and platelet age.

Authors:  L Corash; B Shafer; M Perlow
Journal:  Blood       Date:  1978-10       Impact factor: 22.113

2.  Aggregation of human platelets by bovine or human factor VIII: role of carbohydrate side chains.

Authors:  J Vermylen; M B Donati; G De Gaetano; M Verstraete
Journal:  Nature       Date:  1973-07-20       Impact factor: 49.962

3.  Inhibition of von Willebrand factor-dependent platelet function by increased platelet cyclic AMP and its prevention by cytoskeleton-disrupting agents.

Authors:  B S Coller
Journal:  Blood       Date:  1981-05       Impact factor: 22.113

4.  Studies on the pathophysiology and treatment of von Willebrand's disease. IV. Mechanism of increased ristocetin-induced platelet aggregation in von Willebrand's disease.

Authors:  H Takahashi
Journal:  Thromb Res       Date:  1980-09-15       Impact factor: 3.944

5.  Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease.

Authors:  Z M Ruggeri; F I Pareti; P M Mannucci; N Ciavarella; T S Zimmerman
Journal:  N Engl J Med       Date:  1980-05-08       Impact factor: 91.245

6.  Studies of the human factor VIII/von Willebrand factor protein. III. Qualitative defects in von Willebrand's disease.

Authors:  H R Gralnick; B S Coller; Y Sultan
Journal:  J Clin Invest       Date:  1975-10       Impact factor: 14.808

7.  Factor VIII and human platelet aggregation. III. Further studies on aggregation of humna platelets by neuraminidase-treated human factor VIII.

Authors:  J Vermylen; D Bottecchia; H Szpilman
Journal:  Br J Haematol       Date:  1976-10       Impact factor: 6.998

8.  Prostacyclin inhibits mobilisation of fibrinogen-binding sites on human ADP- and thrombin-treated platelets.

Authors:  J Hawiger; S Parkinson; S Timmons
Journal:  Nature       Date:  1980-01-10       Impact factor: 49.962

9.  Interaction of von Willebrand factor with human platelets in the plasma milieu.

Authors:  J Schullek; J Jordan; R R Montgomery
Journal:  J Clin Invest       Date:  1984-02       Impact factor: 14.808

10.  Von Willebrand disease with an increased ristocetin-induced platelet aggregation and a qualitative abnormality of the factor VIII protein.

Authors:  H Takahashi; N Sakuragawa; A Shibata
Journal:  Am J Hematol       Date:  1980       Impact factor: 10.047

View more
  9 in total

1.  State of the art in platelet function testing.

Authors:  Beate E Kehrel; Martin F Brodde
Journal:  Transfus Med Hemother       Date:  2013-03-18       Impact factor: 3.747

2.  Management of severe chronic thrombocytopenia in von Willebrand's disease type 2B.

Authors:  C Mauz-Körholz; U Budde; H Kruck; D Körholz; U Göbel
Journal:  Arch Dis Child       Date:  1998-03       Impact factor: 3.791

3.  The molecular defect in type IIB von Willebrand disease. Identification of four potential missense mutations within the putative GpIb binding domain.

Authors:  K A Cooney; W C Nichols; M E Bruck; W F Bahou; A D Shapiro; E J Bowie; H R Gralnick; D Ginsburg
Journal:  J Clin Invest       Date:  1991-04       Impact factor: 14.808

4.  Type IIB von Willebrand factor with normal sialic acid content induces platelet aggregation in the absence of ristocetin. Role of platelet activation, fibrinogen, and two distinct membrane receptors.

Authors:  L De Marco; M Mazzuccato; M Grazia Del Ben; U Budde; A B Federici; A Girolami; Z M Ruggeri
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

5.  Functional analysis of a type IIB von Willebrand disease missense mutation: increased binding of large von Willebrand factor multimers to platelets.

Authors:  K A Cooney; S E Lyons; D Ginsburg
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

6.  Reduced survival of type 2B von Willebrand factor, irrespective of large multimer representation or thrombocytopenia.

Authors:  Alessandra Casonato; Lisa Gallinaro; Maria Grazia Cattini; Elena Pontara; Roberto Padrini; Antonella Bertomoro; Viviana Daidone; Antonio Pagnan
Journal:  Haematologica       Date:  2010-03-19       Impact factor: 9.941

7.  von Willebrand factor mutation enhancing interaction with platelets in patients with normal multimeric structure.

Authors:  L Holmberg; J A Dent; R Schneppenheim; U Budde; J Ware; Z M Ruggeri
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

8.  von Willebrand factor synthesized by endothelial cells from a patient with type IIB von Willebrand disease supports platelet adhesion normally but has an increased affinity for platelets.

Authors:  P G de Groot; A B Federici; H C de Boer; P d'Alessio; P M Mannucci; J J Sixma
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

9.  Analysis of the roles of 14-3-3 in the platelet glycoprotein Ib-IX-mediated activation of integrin alpha(IIb)beta(3) using a reconstituted mammalian cell expression model.

Authors:  M Gu; X Xi; G D Englund; M C Berndt; X Du
Journal:  J Cell Biol       Date:  1999-11-29       Impact factor: 10.539

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.